Diabetes

Eli Lilly and Co’s potential weight-loss drug tirzepatide has shown positive results in a Phase III clinical trial, indicating at the therapy’s potential for patients with obesity and diabetes.   Tirzepatide represents a new class of medicines which are currently being investigated for the treatment of obesity. It works by activating the body’s hormone receptors for […]

Scientists at The University of Manchester have found a protein in the skin which could help untreatable wounds heal faster.   The team of scientists published research in the Journal of Investigative Dermatology1showing how the protein arginase1 speeds up the rate of chemical reactions in skin cells. The researchers examined the role arginase1 – a biochemical […]

Research has shown which statins people with diabetes should be taking if they want to lower their “bad” cholesterol and prevent cardiovascular disease.  An analysis of data from 42 clinical trials showed the effectiveness of seven statins in lowering all types of bad cholesterol for patients with diabetes.   Bad cholesterol in the blood, known as non-high-density […]

Early-stage biopharma company Atrogi has received approval from the Federal Institute for Drugs and Medical Devices (BfArM) in Germany to initiate a Phase I study for its drug candidate targeting type 2 diabetes. The approval means that Atrogi will be able to launch a Phase I study for its small molecule drug candidate ATR-258 in […]

PerkinElmer’s SIRION Biotech business and the Centre for Genomic Regulation (CRG) have agreed to jointly develop new generation adeno-associated virus (AAV) vectors for Type 1 and Type 2 diabetes gene therapy in the pancreas.  The collaboration  The collaboration combines SIRION’s AAV technology platform and expertise in viral vector development and production with CRG’s deep knowledge […]

The National Institute for Health and Care Excellence (NICE) in the UK has issued a Final Appraisal Document (FAD) recommending AstraZeneca’s Forxiga (dapagliflozin) within its marketing authorisation for the treatment of adults with chronic kidney disease (CKD).1  Conditions  Dapagliflozin is recommended as an option for treating CKD in adults. It is recommended only if:  it […]

Professor Di Yu of the UQ Diamantina Institute collaborated with scientists from the Chinese Academy of Sciences and Beijing Chaoyang Hospital to address age-related macular degeneration and retinal neovascularisation linked to diabetes, which affect approximately 450 million people worldwide. This has been published in Nature Biomedical Engineering.  Currently, treatments for these diseases are delivered via an injection in the […]

Professor of Cellular Immunology at the University of Dundee’s School of Life Sciences, Doreen Cantrell, has been selected to join GSK’s Immunology Network, a programme designed to embed academic scientists in GSK laboratories with the goal to broaden scientific insight and drive major breakthroughs in applied immunology.  Professor Cantrell is an immunologist and an authority […]

Glyscend has presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, from a study of its proprietary oral polymer duodenal exclusion therapy. The positive data were presented ahead of Glyscend’s Phase I clinical trials, which have commenced recruiting healthy subjects in South Australia. Glyscend is developing a new class of oral gut-restricted […]

A potential improved treatment for two of the leading causes of blindness – age and diabetes-related eye problems – has been demonstrated in research involving University of Queensland expert Professor Di Yu of the UQ Diamantina Institute, who collaborated with scientists from the Chinese Academy of Sciences and Beijing Chaoyang Hospital to address an issue […]